



# Chronic Pain and Mental Health Disorders: Shared Neural Mechanisms, Epidemiology, and Treatment

W. Michael Hooten, MD

## CME Activity

**Target Audience:** The target audience for *Mayo Clinic Proceedings* is primarily internal medicine physicians and other clinicians who wish to advance their current knowledge of clinical medicine and who wish to stay abreast of advances in medical research.

**Statement of Need:** General internists and primary care physicians must maintain an extensive knowledge base on a wide variety of topics covering all body systems as well as common and uncommon disorders. *Mayo Clinic Proceedings* aims to leverage the expertise of its authors to help physicians understand best practices in diagnosis and management of conditions encountered in the clinical setting.

**Accreditation:** Mayo Clinic College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**Credit Statement:** Mayo Clinic College of Medicine designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s).™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**MOC Credit Statement:** Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**Learning Objectives:** On completion of this article, you should be able to: (1) distinguish key brain regions responsible for nociceptive processing; (2) identify highly prevalent comorbid mental health disorders as they occur in the context of chronic pain; and (3) formulate an evidence-based treatment plan for adults with chronic pain and mental health disorders.

**Disclosures:** As a provider accredited by ACCME, Mayo Clinic College of Medicine (Mayo School of Continuous Professional Development)

must ensure balance, independence, objectivity, and scientific rigor in its educational activities. Course Director(s), Planning Committee members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of this information will be published in course materials so that those participants in the activity may formulate their own judgments regarding the presentation. In their editorial and administrative roles, William L. Lanier, Jr, MD, Terry L. Jopke, Kimberly D. Sankey, and Nicki M. Smith, MPA, have control of the content of this program but have no relevant financial relationship(s) with industry. The authors report no competing interests.

**Method of Participation:** In order to claim credit, participants must complete the following:

1. Read the activity.
2. Complete the online CME Test and Evaluation. Participants must achieve a score of 80% on the CME Test. One retake is allowed.

Visit [www.mayoclinicproceedings.org](http://www.mayoclinicproceedings.org), select CME, and then select CME articles to locate this article online to access the online process. On successful completion of the online test and evaluation, you can instantly download and print your certificate of credit.

**Estimated Time:** The estimated time to complete each article is approximately 1 hour.

**Hardware/Software:** PC or MAC with Internet access.

**Date of Release:** 6/22/2016

**Expiration Date:** 6/30/2018 (Credit can no longer be offered after it has passed the expiration date.)

**Privacy Policy:** <http://www.mayoclinic.org/global/privacy.html>

**Questions?** Contact [dletcsupport@mayo.edu](mailto:dletcsupport@mayo.edu).



From the Division of Pain Medicine, Department of Anesthesiology, Mayo Clinic College of Medicine, Rochester, MN.

## Abstract

Chronic pain and mental health disorders are common in the general population, and epidemiological studies suggest that a bidirectional relationship exists between these 2 conditions. The observations from functional imaging studies suggest that this bidirectional relationship is due in part to shared neural mechanisms. In addition to depression, anxiety, and substance use disorders, individuals with chronic pain are at risk of other mental health problems including suicide and cigarette smoking and many have sustained sexual violence. Within the broader biopsychosocial model of pain, the fear-avoidance model explains how behavioral factors affect the temporal course of chronic pain and provides the framework for an array of efficacious behavioral interventions including cognitive-behavioral therapy, acceptance-based therapies, and multidisciplinary pain rehabilitation. Concomitant pain and mental health disorders often complicate pharmacological management, but several drug classes, including serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, and anticonvulsants, have efficacy for both conditions and should be considered first-line treatment agents.

© 2016 Mayo Foundation for Medical Education and Research ■ Mayo Clin Proc. 2016;91(7):955-970

Chronic pain and mental health disorders are common in the general population; the prevalence of chronic pain ranges from 2% to 40%,<sup>1</sup> and the prevalence of mental health disorders range from 17% to 29%.<sup>2,3</sup> Concomitant with the high prevalence of both conditions, epidemiological and functional imaging studies suggest that a bidirectional relationship exists between chronic pain and mental health disorders. This is relevant to clinical practice because this bidirectional relationship may be partly mediated by shared neural mechanisms, which, in turn, may necessitate the use of targeted pharmacological and behavioral interventions aimed at treating both conditions. In addition, adults with chronic pain are at risk of other mental health problems including suicide and cigarette smoking and many have sustained sexual violence. Therefore, the objectives of this review were to (1) provide a working definition of the pain matrix, which is a proposed neural network responsible for the experience of chronic pain; (2) summarize the prevalence of commonly occurring mental health disorders in frequently encountered chronic pain conditions; and (3) identify behavioral and pharmacological treatments with efficacy for both chronic pain and mental health disorders.

## METHODS

Similar to previously published strategies, databases of MEDLINE using the PubMed and Ovid platforms were searched using the keywords *pain matrix*, *neuromatrix*, *chronic pain*, *depression*, *anxiety*, *substance use*, and *suicide* with no date restrictions.<sup>4</sup> Keywords related to specific topics (eg, low back pain, fibromyalgia, migraine headache, behavioral treatment, and antidepressants) were cross-referenced with the initial search terms using the identified databases. Search terms were cross-referenced with review articles, and additional articles were identified by manually searching the reference lists.

## Pain Matrix

The term *pain matrix* refers to a constellation of brain regions activated by nociceptive stimuli. The neurobiological tenets of the pain matrix stem from the conceptual framework of the neuromatrix that was espoused by

Melzack<sup>5</sup> to describe a pattern of neural activation initially believed to represent the “neurosignature” of pain. However, numerous neuroimaging studies have since shown that brain regions activated by nociceptive stimuli can also be affected by various emotional and behavioral states.<sup>6</sup> This is relevant because the pain matrix provides the neural mechanistic basis for better understanding of how psychological factors affect pain.


The pain matrix was originally conceptualized as a constellation of interrelated brain regions functioning as a uniplanar circuit. However, a growing body of research suggests that the pain matrix may be more accurately construed as a hierarchical multilevel neural network progressing from the encoding of nociceptive stimuli to the conscious modulation and memory formation of the pain experience. Garcia-Larrea and Peyron<sup>7</sup> have proposed a pain matrix composed of 3 tiers, or levels, of interrelated neural activity (Figure 1). In this 3-tiered model, “first-order” processing refers to nociceptive activation of the spinothalamic tract, which comprises neurons in the dorsal horn of the spinal cord with axonal projections terminating in the posterior thalamus. Nociceptive stimuli are then posited to undergo “second-order” processing in the anterior cingulate cortex (ACC), insula, prefrontal cortex (PFC), and posterior parietal cortex. As a result, nociceptive stimuli are consciously perceived, subjected to attentional and cognitive modulation, and transformed into somatic, or “vegetative,” responses. The perception and modulation of pain is further affected, or “reappraised,” by the emotional context of the stimuli and further individualized by psychological factors that together coalesce in memory formation. Neural structures implicated in this final “third-order” process include the orbitofrontal, perigenual ACC, and anterolateral PFC regions. Brain regions comprising the second and third tiers interact with various descending tracts in the spinal cord, resulting in either inhibitory or facilitatory modulation of incoming nociceptive stimuli in a process termed *descending control*. In this 3-tiered model of the pain matrix, the experience of pain is the consequence of progressively complex and interrelated “orders” of neural activity aptly designated by Garcia-Larrea and Peyron<sup>7</sup> as the “nociceptive,”

“perceptive-attentional,” and “reappraisal-emotional” matrices.

### Epidemiology and Neurobiological Links Between Chronic Pain and Mental Health Disorders

**Depression.** The presence of depressive symptoms are often quantified using self-report questionnaires, and elevated levels suggest the presence of a mood disorder<sup>8,9</sup> (Table 1). However, in epidemiological studies, the presence of common mood disorders, including major depressive disorder, dysthymia, and bipolar disorder, are generally best identified using semi-structured interviews. The estimated current or 12-month prevalence of high levels of depressive symptoms or a mood disorder exceeds 50% in individuals with fibromyalgia,<sup>17-23</sup> temporomandibular joint disorder,<sup>24,25</sup> chronic spinal pain,<sup>26-29</sup> and chronic abdominal pain<sup>30-32</sup> (Table 2). The estimated prevalence of depression exceeds 20% in individuals with arthritis,<sup>23,37,38,47-49</sup> migraine headache,<sup>37-41</sup> and pelvic pain,<sup>42-46</sup> whereas the prevalence is lowest in individuals with neuropathic pain.<sup>33-36</sup> Across all chronic pain groups, the prevalence of major depressive disorder ranges from 2% to 61%,<sup>19,21,23,26-29,37,38,40,42,43,47,49,57,58</sup> the prevalence of dysthymia ranges from 1% to 9%,<sup>21,26-29,37,40,49,57,58</sup> and the prevalence of bipolar disorder ranges from 1% to 21%.<sup>21,22,29,40,49</sup>

The frequent co-occurrence of chronic pain and depression reflects the shared risks that exist between these 2 conditions as exemplified in the following 2 examples. First, in a population-based study<sup>59</sup> involving 845 adults, study participants with mild or disabling neck or low back pain were 2.0 to 2.5 times more likely to experience an episode of depression at 6- and 12-month follow-up than individuals without spinal pain. Conversely, pain-free individuals with severely elevated levels of depressive symptoms (n=790) were 4 times more likely to develop neck or low back pain at 6- and 12-months follow-up than individuals with low levels of depressive symptoms.<sup>60</sup> More specifically, the rate of neck or back pain increased by 4% for every 1-point increase in the severity of depressive symptoms.<sup>60</sup> Second, in a population-based study<sup>61</sup> involving 118,533 individuals, study participants with “chronic back pain” were 6 times more likely



to be depressed than pain-free participants. Conversely, pain-free individuals subsequently diagnosed with depression were approximately 3 times more likely to develop chronic back pain than individuals without depression.<sup>62</sup> In addition, the rate of depression increased with greater pain severity.<sup>61</sup> Collectively, these 2 examples suggest that a bidirectional relationship exists between chronic spinal pain and depression, in which spinal pain is a risk factor for depression and depression is a risk factor for spinal pain. These studies also suggest that the bidirectional relationship is affected, in part, by

**TABLE 1. Sensitivities and Specificities of Screening Questionnaire Cutoff Scores for Depression, Anxiety, and Substance Use Disorders**

Variable	Cutoff score	Sensitivity (%)	Specificity (%)
<b>Depression</b>			
Beck Depression Inventory <sup>8</sup>	15	77	61
Hamilton Rating Scale for Depression <sup>8</sup>	17	81	65
Center for Epidemiologic Studies Depression Scale <sup>9</sup>	27	82	68
Patient Health Questionnaire Depression <sup>8</sup> (PHQ-9)	10	79	60
<b>Anxiety</b>			
Hospital Anxiety and Depression Scale—Anxiety <sup>10,11</sup>	8	88	81
Beck Anxiety Inventory <sup>12</sup>	5.5	76	77
Patient Health Questionnaire Anxiety <sup>13</sup> (Generalized Anxiety Disorder-7)	10	89	82
<b>Substance use disorders</b>			
Alcohol Use Disorders Identification Test <sup>14</sup>	8	88	77
CAGE questionnaire for alcohol misuse <sup>15</sup>	2	71	90
Drug Abuse Screening Test <sup>16</sup>	2	85	78
Current Opioid Misuse Measure <sup>16</sup>	10	84	82

a dose-response phenomenon between pain intensity and the severity of depressive symptoms.

Functional imaging studies support the bidirectional relationship between pain and depression. Various chronic pain conditions, including fibromyalgia, abdominal pain, and low back pain, have been associated with functional imaging alterations in brain regions responsible for processing emotional stimuli, including the ACC and PFC.<sup>63-66</sup> Conversely, in adults with depression, emotional processing in the insula has been reported to shift toward an insular region associated with processing pain stimuli in healthy individuals.<sup>67,68</sup>

**Anxiety.** *Anxiety* is a term used to describe excessive fear or worry, and individuals with high levels of anxiety can be identified using various screening questionnaires<sup>10-13</sup> (Table 1). Anxiety disorders are a group of conditions sharing features of excessive fear and anticipation of future threat; examples of commonly occurring anxiety disorders include generalized anxiety disorder (GAD), panic disorder, agoraphobia, and posttraumatic stress disorder (PTSD). The estimated current or 12-month prevalence of high levels of anxiety or the presence of an anxiety disorder exceeds 50% in individuals with temporomandibular joint disorder,<sup>50-52</sup> fibromyalgia,<sup>18-21,23</sup> and chronic abdominal pain,<sup>30,32</sup>

whereas the prevalence exceeds 35% to 40% in individuals with migraine headache,<sup>38,39,41</sup> pelvic pain,<sup>42,53</sup> and arthritis<sup>23,37,38,48,49</sup> (Table 2). The prevalence of anxiety was lowest in individuals diagnosed with spinal pain<sup>26-29,38</sup> or neuropathic pain.<sup>34-36</sup> Across all chronic pain groups, the prevalence of GAD ranges from 1% to 10%<sup>19,21,23,26,28,29,37,38,49,58</sup> and the prevalence of panic disorder ranges from 1% to 28%.<sup>19,23,26-29,37,38,49,58</sup> Similarly, the prevalence of agoraphobia across all pain groups ranges from 1% to 8%<sup>26,28,29,37,49,58</sup> and the prevalence of PTSD ranges from 1% to 23%.<sup>21,23,26,28,29,37,49</sup>

Similar to depression, a bidirectional relationship exists between chronic pain and anxiety. This is particularly evident in individuals with migraine headache. In population-based studies, individuals with migraine are 2 to 3 times more likely to be diagnosed with GAD, panic disorder, agoraphobia, or PTSD than individuals without migraine.<sup>40</sup> Conversely, individuals with anxiety disorders are twice as likely to develop migraine headache than individuals without anxiety disorders.<sup>69</sup> The observations from functional neuroimaging studies support this bidirectional relationship, suggesting that overlapping brain areas (thalamus, PFC, and ACC) are activated by both chronic pain and anxiety.<sup>70-72</sup>

**Substance Abuse.** Opioid use disorder (OUD) is a major threat to US public health.<sup>73,74</sup> In adults with chronic pain receiving long-term opioid therapy, the estimated current prevalence of OUD in 2 systematic reviews<sup>75,76</sup> ranges from 1% to 43%. In these 2 reviews,<sup>75,76</sup> the current prevalence of OUD in studies assessed to be of high methodological quality ranges from 1% to 23%. Important substance use-related risk factors for current and lifetime OUD in adults with chronic pain receiving long-term opioid therapy include a history of opioid abuse, history of substance abuse treatment, and history of illicit drug use including cannabis.<sup>77-80</sup> Despite the importance of OUD, individuals with chronic pain are at risk of other substance use disorders (SUDs), which can be identified using various screening questionnaires<sup>14-16</sup> (Table 1). The estimated current or 12-month prevalence of alcohol and other nonopioid SUDs is highest in adults with fibromyalgia,<sup>19,20,23</sup> chronic spinal pain,<sup>26-29</sup> or

arthritis<sup>23,49</sup> and lowest in individuals with neuropathic pain<sup>54-56</sup> or migraine headache<sup>40</sup> (Table 2). Across all pain groups, the prevalence of alcohol abuse or dependence ranges from 2% to 22%<sup>19,23,26-29,40,49,55</sup> and the combined prevalence of drug abuse, drug dependence, or any SUD (OUD not specified) ranges from 1% to 25%.<sup>19,20,27-29,40,49,54,56</sup>

Akin to depression and anxiety, a bidirectional relationship exists between chronic pain and SUD. The estimated prevalence of chronic pain in individuals with SUD ranges from 27% to 87%.<sup>81-83</sup> In population-based studies, individuals with chronic pain are approximately 2 to 3 times more likely to develop an SUD than individuals without chronic pain,<sup>84</sup> and individuals with SUD are approximately 1.5 times more likely to develop chronic pain.<sup>85</sup>

Functional imaging and preclinical studies support the bidirectional relationship between chronic pain and SUD. For example, the medial PFC is involved in processing pain stimuli. In addition, the medial PFC and the nucleus accumbens are key components of the mesocorticolimbic circuitry, which is the principal reward system of the brain and plays a key role in the neurobiology of SUD.<sup>86,87</sup> In response to nociceptive stimuli, connectivity between the medial PFC and the nucleus accumbens may potentiate the development of chronic pain.<sup>88,89</sup> In addition to shared neural circuits, preclinical studies suggest that the transition from acute to chronic pain and opioid tolerance share common cellular mechanisms.<sup>90</sup>

### Other Mental Health Conditions


**Suicide.** In 2013, the rate of suicide in the United States was 12.6 per 100,000 person-years, which is equivalent to 113 suicides daily.<sup>91</sup> For the same time point, suicide was the 10th leading cause of death overall (n=41,419) and the 2nd leading cause of death among all people 15 to 34 years of age (n=11,226).<sup>91</sup> In a large study involving approximately 260,000 veterans, the rate of suicide among veterans with mild to severe pain ranged from 45 to 81 per 100,000 person-years.<sup>92,93</sup> Suicidal ideation is a frequently occurring symptom in 28% to 48% of treatment-seeking adults with chronic pain.<sup>94-96</sup> In addition to suicide risk factors

**TABLE 2. Estimated Prevalence of Depression, Anxiety, and Substance Use Disorders in Commonly Occurring Chronic Pain Conditions**

Variable	Prevalence (%)
<b>Depression</b>	
Spinal pain (lumbar, thoracic, or neck) <sup>26-29</sup>	2-56
Neuropathic pain <sup>33-36</sup>	4-12
Fibromyalgia <sup>17-23</sup>	21-83
Migraine headache <sup>37-41</sup>	17-28
Temporomandibular joint disorder <sup>24,25</sup>	16-65
Pelvic pain <sup>42-46</sup>	19-22
Abdominal pain <sup>30-32</sup>	9-54
Arthritis <sup>23,37,38,47-49</sup>	3-39
<b>Anxiety</b>	
Spinal pain (lumbar, thoracic, or neck) <sup>26-29,38</sup>	1-26
Neuropathic pain <sup>34-36</sup>	5-27
Fibromyalgia <sup>18-21,23</sup>	18-60
Migraine headache <sup>38,39,41</sup>	2-45
Temporomandibular joint disorder <sup>50-52</sup>	15-65
Pelvic pain <sup>42,53</sup>	12-41
Abdominal pain <sup>30,32</sup>	21-51
Arthritis <sup>23,37,38,48,49</sup>	1-35
<b>Substance use disorder</b>	
Spinal pain (lumbar, thoracic, or neck) <sup>26-29</sup>	4-14
Neuropathic pain <sup>54-56</sup>	1-9
Fibromyalgia <sup>19,20,23</sup>	1-25
Migraine headache <sup>40</sup>	1-6
Arthritis <sup>23,49</sup>	1-12
Current and 12-mo prevalence rates grouped together.	

found in the general population, important pain-related risk factors include high levels of comorbid mental health problems, high pain intensity, analgesic medication use, and pain-related psychological factors<sup>92,97</sup> (Figure 2). Diagnostic groups that may be at increased risk include individuals with chronic back pain, migraine headache, and fibromyalgia.<sup>92</sup> Because of high rates of suicidality, clinicians should regularly ask patients with chronic pain about suicidal thoughts and behaviors and be prepared to implement the appropriate level of clinical care<sup>92</sup> (Figure 2).

**Sexual Violence and Abuse.** Approximately 1 in 5 women (18%) and 1 in 71 men (1%) in the United States have been raped.<sup>98</sup> In addition, an estimated 13% of women and 6% of men have experienced sexual coercion and 27% of women and 12% of men have experienced unwanted sexual contact.<sup>98</sup> Survivors of sexual violence and abuse are at risk for developing chronic pain and other health problems (eg, irritable bowel syndrome and



psychogenic seizures).<sup>99,100</sup> More specifically, individuals with a history of rape or sexual abuse are approximately 2.5 to 3.5 times more likely to develop fibromyalgia, chronic musculoskeletal pain, or chronic pelvic pain.<sup>100</sup> Although the neural mechanisms linking the associations between sexual violence and chronic pain have not been fully elucidated, targets of ongoing research include genetic and epigenetic factors, stress-related disruption of the hypothalamic-pituitary axis, and immune dysfunction.<sup>101</sup> In clinical practice, screening patients for a history of sexual violence and abuse is critically important because most survivors do not volunteer this information to health care professionals.<sup>102</sup>

**Personality Characteristics and Disorders.** The area of personality characteristics and personality disorders (PDs) is a broad field of study. Consequently, the ensuing discussion will be limited to the personality characteristic of neuroticism and commonly occurring PDs. *Neuroticism* can generally be defined as the propensity to experience negative emotions (eg, fear, worry, frustration, jealousy, and anger). Higher levels of neuroticism in individuals with chronic pain have been associated with increased reactivity to pain,<sup>103</sup> greater disability and lower quality of life,<sup>104</sup> use of passive coping strategies,<sup>105</sup>

greater pain-related suffering,<sup>106</sup> and greater pain-related anxiety.<sup>107</sup>

Personality disorder is generally used to describe a “pervasive disturbance in how an individual experiences and thinks about the self, others, and the world, manifested in maladaptive [and inflexible] patterns of cognition...emotional expression, and behavior.”<sup>108,p722</sup> In the general population, the prevalence of PD ranges from 4% to 6%, but the prevalence in individuals in the health care setting ranges from 25% to 50%.<sup>108</sup> In individuals with chronic pain, the prevalence of borderline PD (impulsivity and instability in relationships, self-image, affect) ranges from 1% to 28%; that of narcissistic PD (grandiosity, need for admiration, and lack of empathy) ranges from 2% to 23%; that of histrionic PD (excessive emotionality and attention seeking) ranges from 6% to 23%; that of dependent PD (submissive and excessive care needs) ranges from 2% to 17%; and that of obsessive-compulsive PD (excessive orderliness, perfectionism, and control) ranges from 7% to 16%.<sup>21,27,109</sup>

When a patient with a difficult personality characteristic or PD is encountered in clinical practice, referral to a mental health professional should be considered for a diagnostic assessment and development of a treatment plan. In general, the mainstay of treatment is psychotherapy including cognitive-behavioral therapy (CBT) (eg, for the treatment of


obsessive-compulsive PD) and dialectical behavioral therapy (eg, for the treatment of borderline PD).<sup>110</sup>

**Cigarette Smoking.** The prevalence of smoking in the general population has declined to 19.3% over the past decade.<sup>111</sup> However, the prevalence of smoking in patients seeking treatment for chronic pain was 24.2% in 2000 and 28.3% in 2010.<sup>112</sup> This is important because smoking remains the single greatest preventable cause of death in the United States<sup>113</sup> The increased prevalence of smoking may be due in part to clinical characteristics unique to adults with chronic pain. For example, smokers with chronic pain report greater pain severity partly due to greater levels of depression and greater levels of functional impairment.<sup>114,115</sup> In addition, smokers with chronic pain are more likely to use opioids and consume higher doses of opioids because of the use of greater quantities by men.<sup>116,117</sup> These clinical observations related to opioid use are supported by preclinical studies suggesting that the antinociceptive effects of nicotine and morphine are linked, and morphine-related antinociception is affected by activation of centrally located nicotinic acetylcholine receptors.<sup>118</sup> Smokers with chronic pain also report that smoking is an important coping strategy for pain and distress, which could partly explain why it is difficult for these individuals to quit smoking.<sup>115,119</sup> Thus, this patient group may require specifically tailored smoking cessation interventions that incorporate behavioral treatments of chronic pain.<sup>120</sup>

### Behavioral Treatment

Although pain is an individualized and internal experience, clinically observable signs and symptoms of pain are complex and multifaceted forms of behavior. When viewed from the biopsychosocial perspective, the clinical manifestations of pain can be conceptualized as the interrelationship between biological factors, psychological processes, and social influences. Within the broader biopsychosocial model, several behavioral models, particularly the fear-avoidance model, have been developed to explain how psychological factors affect the temporal course of pain and provide the framework for a range of behavioral treatments.

**Fear-Avoidance Model of Pain.** The fear-avoidance model is one of the most widely recognized theoretical constructs used to explain how psychological processes mediate the transition of episodic acute pain to chronic pain with associated disability<sup>121</sup> (Figure 3). The underpinnings of this model are key psychological processes, including emotions, cognitions, attention, and behaviors, that coalesce to form fear-avoidance beliefs and behaviors, which, in turn, become the key drivers of pain-related disability.<sup>122</sup> In the fear-avoidance model, the primary factor is the emotion of fear, which develops in response to negative cognitions exaggerating the potential threat of pain, including an exaggerated negative interpretation of pain-related health information. This exaggerated set of pain-related cognitions is termed *pain catastrophizing*, which is often manifested clinically as the anticipation of the worst possible outcome in association with a negative affect (eg, depressive symptoms and anxiety). Fear serves to focus attention on pain and associated symptoms, leading to a state of hypervigilance and subsequent avoidance of activities (occupational and social) and body



**FIGURE 3.** Schematic representation of the fear-avoidance model of chronic pain.

movements (walking and physical therapy modalities) perceived to potentially worsen pain.<sup>122</sup> These psychological processes and resultant avoidant beliefs and behaviors do not necessarily evolve in a sequential pattern; rather, these interrelated phenomena occur simultaneously and set into play a self-perpetuating and deleterious cycle culminating in a state of physical disuse and disability.

In accordance with the 3-tiered model of the pain matrix, functional imaging research supports the theoretical constructs of the fear-avoidance model.<sup>7</sup> For instance, the anticipation of pain has been associated with activation of brain regions comprising the “perceptive-attentional” and “reappraisal-emotional” tiers in individuals with chronic pain with high levels of pain catastrophizing, fear-avoidance beliefs, and negative affect.<sup>123</sup>

**Cognitive-Behavioral Therapy.** Cognitive-behavioral therapy is widely used to treat pain-related functional disabilities. In general, CBT is a skills-based intervention that emphasizes identifying and changing maladaptive cognitions, emotions, and behaviors. Brief (eg, 1-2 sessions) or longer-term (eg, successive sessions during a 2- to 4-month time period) treatment can be delivered in either individual or group-based sessions. When applied within the fear-avoidance model, CBT targets the deleterious effects of pain catastrophizing and avoidant beliefs (eg, examples of maladaptive cognitions), fear (eg, example of a maladaptive emotion), and avoidant behaviors (eg, a set of maladaptive behaviors) with the goal of developing and adopting coping strategies aimed at enhancing an active problem-solving approach to successfully confront and self-manage health-related threats posed by pain. Although CBT therapists use various techniques, several components are considered “core elements” of this approach, including (1) graded homework assignments (eg, typically using a workbook style manual); (2) cognitive restructuring (eg, teaching how to challenge maladaptive cognitions); (3) relaxation training (eg, diaphragmatic breathing, progressive muscle relaxation, and imagery); (4) time-based activity pacing (eg, activity pace based on time rather than task accomplishment); and (5) extinguishing *pain behaviors* (defined as verbal and nonverbal expressions

of pain).<sup>124</sup> Other techniques include distraction (eg, actively diverting attention away from pain), reinterpretation (eg, changing thoughts about pain), dissociation (eg, separating feelings of pain from other sensations), coping self-statements (eg, affirming self-statements), and emotional disclosure (eg, expressive writing).<sup>125</sup>

Cognitive-behavioral therapy yields long-term improvements in pain intensity, disability, quality of life, pain-related coping, depressed mood, and health care-seeking behaviors.<sup>126-128</sup> The favorable effects of CBT on clinical pain outcomes is supported by functional imaging research. In a cohort of adults with fibromyalgia, functional imaging after CBT exhibited increased activation of brain regions associated with executive cognitive control, suggesting that CBT enhances access to cognitive regions involved in the reappraisal of pain.<sup>129</sup>

**Acceptance-Based Therapies.** Acceptance-based therapies emphasize that inflexible beliefs about chronic pain (eg, chronic pain is curable and expectation for total pain relief) halt the pursuit of highly regarded life values, resulting in a state of despondency and disability.<sup>130</sup> Two widely used acceptance-based approaches for chronic pain include acceptance and commitment therapy and mindfulness-based stress reduction. Acceptance and commitment therapy promotes awareness and nonjudgmental acceptance of chronic pain while identifying and committing to pursue goals supporting highly regarded life values. An important outcome of therapy is enhanced functioning through the contextual acceptance of pain. Acceptance and commitment therapy differs from CBT, which focuses on recognizing, evaluating, and making changes to unhelpful pain-related thoughts, emotions, and behaviors. Mindfulness-based stress reduction uses mindfulness meditation to develop intentional and nonjudgmental awareness of the present moment. After 6 to 8 weeks of mentored training, individuals develop the ability to sustain an open and accepting state of consciousness in which self-regulated attention is maintained on momentary experience.

The effects of acceptance-based therapies on clinical outcomes of chronic pain have

been mixed. For example, in 2 systematic reviews<sup>131,132</sup> that included trials of acceptance and commitment therapy and mindfulness-based stress reduction, small to moderate effects were observed for pain, depression, anxiety, quality of life, and physical well-being. However, in 2 systematic reviews that included only mindfulness-based interventions, small effects on pain, depression, and anxiety were found at 2- to 6-months follow-up,<sup>133</sup> but no significant effects were observed when the meta-analyses were restricted to studies incorporating active control groups.<sup>134</sup> Functional imaging studies suggest that mindfulness meditation reduces activation of the primary somatosensory cortex and increases activity in brain regions implicated in the cognitive regulation and reappraisal of pain.<sup>135</sup>

**Multidisciplinary Pain Rehabilitation.** *Multidisciplinary pain rehabilitation* (MPR), otherwise termed *interdisciplinary pain rehabilitation*, refers to an integrated approach to treat chronic pain by a team of health care professionals who share common treatment objectives. Typically, treatment is delivered within the broader context of the biopsychosocial model, and group-based CBT is used to target pain-related impairments in physical and emotional functioning. The goals of treatment include improvements in functioning, which are achieved through the integrated delivery of group-based treatments (eg, group-based CBT, physical therapy, and occupational therapy) provided by psychologists, physicians, physical and occupational therapists, nurses, vocational specialists, and pharmacists.<sup>136</sup> The clinical milieu of an MPR program also provides an optimal environment to initiate and complete medically directed opioid tapering, which is being increasingly recognized as an unmet need for many patients.<sup>137</sup> Most MPR programs are delivered in the outpatient setting, and in highly intensive programs, treatment is provided 6 to 8 hours daily for 15 consecutive working days. In less intensive programs, treatment is provided 2 to 4 hours daily, 2 to 3 times weekly for a 4- to 6-week period.

Multidisciplinary pain rehabilitation has been associated with significant improvements in pain intensity, functional disability, and sustained employment<sup>138</sup> and reductions in a broad range of medical costs.<sup>139</sup> Aerobic and

strengthening exercises during the course of MPR have been associated with significant improvements in several key physiological measures of strength, aerobic fitness, and pain perception.<sup>140-142</sup> Opioid tapering during MPR has been associated with significant reductions in medication costs<sup>143,144</sup> without adversely affecting immediate or long-term treatment outcomes.<sup>145-147</sup>

### Psychopharmacological Treatment

Pain often complicates the pharmacological treatment of mental health disorders; conversely, mental health disorders can complicate the pharmacological treatment of pain. The ensuing content will be limited to medications with dual analgesic and psychotropic properties including serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and anticonvulsant medications.

### Serotonin-Norepinephrine Reuptake Inhibitors.

Serotonin-norepinephrine reuptake inhibitors are selective for both serotonin and norepinephrine; the selective reuptake of norepinephrine is believed to be responsible for the analgesic effects of SNRIs. The most widely used SNRIs are duloxetine, venlafaxine, and milnacipran (Table 3). The active metabolite of venlafaxine (desvenlafaxine) and the levo enantiomer of milnacipran (levomilnacipran) are commercially available in the United States as antidepressant medications. Proposed mechanisms of action include norepinephrine-mediated activation of descending inhibitory pathways projecting from the supraspinal centers and terminating in the dorsal horn of the spinal cord. Another possible mechanism includes improvement of depressive symptoms. For example, secondary analyses of 4 randomized trials of duloxetine for fibromyalgia revealed that 69% of pain improvement was attributed to the direct analgesic effects of the drug whereas 31% of pain improvement was attributed to reductions in depressive symptoms.<sup>152</sup> In addition to fibromyalgia,<sup>149,153</sup> neuropathic pain,<sup>150</sup> and musculoskeletal pain,<sup>148,154</sup> SNRIs are effective for the treatment of major depressive disorder<sup>155</sup> and anxiety disorders<sup>156</sup> including GAD and panic disorder. As specifically exemplified in the treatment of depression,<sup>157</sup> the effects of antidepressant medications on mental health

TABLE 3. Summary of Medications With Dual Analgesic and Mental Health Effects<sup>a</sup>

Medication	FDA indication		NNT (95% CI)	Dosing
	Pain	Mental health	Pain	
SNRI				
Duloxetine	C-MSP DPN Fibromyalgia	GAD MDD	C-MSP: 6.0 (4.0-11.0) <sup>148</sup> FM: 8.2 (6.0-13.2) <sup>149</sup> NP <sup>b</sup> : 6.4 (5.2-8.4) <sup>150</sup>	60-120 mg/d, single or 2 divided doses
Venlafaxine	—	GAD MDD Panic disorder Social phobia	NP <sup>b</sup> : 6.4 (5.2-8.4) <sup>150</sup>	150-225 mg/d, single dose extended release formulation
Milnacipran	Fibromyalgia	—	FM: 11.0 (8.3-16.3) <sup>149</sup>	100-200 mg/d, 2 divided doses
TCA				
Amitriptyline	—	Depression	NP <sup>b</sup> : 3.6 (3.0-4.4) <sup>150</sup> FM: 3.5 (2.7-5.0) <sup>149</sup>	50-150 mg/d, single dose
Nortriptyline	—	Depression	NP <sup>b</sup> : 3.6 (3.0-4.4) <sup>150</sup>	50-100 mg/d, single dose
Anticonvulsant				
Pregabalin	DPN Fibromyalgia SCI pain PHN	—	NP <sup>b</sup> : 7.7 (6.5-9.4) <sup>150</sup> FM: 6.6 (5.0-9.9) <sup>151</sup>	150-600 mg/d, 2 divided doses
Gabapentin	PHN	—	NP <sup>b</sup> : 7.2 (5.9-9.1) <sup>150</sup> FM: 5.0 (2.8-21.7) <sup>151</sup>	1800-3600 mg/d, 3 divided doses

<sup>a</sup>C-MSP = chronic musculoskeletal pain; DPN = diabetic peripheral neuropathy; FDA = Food and Drug Administration; FM = fibromyalgia; GAD = generalized anxiety disorder; MDD = major depressive disorder; NNT = number needed to treat; NP = neuropathic pain; PHN = postherpetic neuralgia; SCI = spinal cord injury; SNRI = serotonin-norepinephrine reuptake inhibitor; TCA = tricyclic antidepressant.

<sup>b</sup>Neuropathic pain diagnostic groups and/or drug class combined to yield a pooled NNT value.

outcomes can be adversely affected by pain, but concurrent behavioral treatment may mitigate these adverse effects.<sup>158</sup>

In individuals with major depressive disorder, duloxetine has been associated with reductions in activation of the ACC and right PFC<sup>159</sup> and milnacipran has been associated with increased activity in brain regions linked to the descending inhibitory pain pathways in adults with fibromyalgia.<sup>160</sup>

**Tricyclic Antidepressants.** Tricyclic antidepressants were one of the first drug classes used to treat depression and the first antidepressants used to treat pain. Similar to SNRIs, the proposed analgesic effects of TCAs are mediated by activation of descending inhibitory pathways, but other possible mechanisms include blockade of voltage-gated sodium channels,<sup>161</sup> inhibition of *N*-methyl-D-aspartate receptors,<sup>162</sup> and interaction with opioid receptors.<sup>163</sup> The major adverse effects of TCAs are related to blockade of muscarinic (eg, urinary retention, constipation tachycardia, blurred vision, and delirium), histamine

(H<sub>1</sub>) (eg, sedation and weight gain), and  $\alpha_1$ -adrenergic (eg, orthostatic hypotension) receptors. Type 1 antiarrhythmic properties are due to sodium channel blockade, which could, in part, account for the increased rate of sudden cardiac death and myocardial infarction.<sup>164,165</sup> Although neuropathic pain is the most widely recognized pain indication for TCA use,<sup>150</sup> these medications, particularly nortriptyline and amitriptyline, also have proven efficacy for fibromyalgia<sup>149,153</sup> and chronic low back pain.<sup>166</sup> In the present era, TCAs are not generally considered to be first-line treatment agents for mental health disorders because of the availability of other medications with more favorable adverse effect profiles. Amitriptyline has been associated with reduced activation of the ACC and posterior parietal region in adults with chronic abdominal pain.<sup>167</sup>


**Anticonvulsants.** Numerous anticonvulsants, particularly gabapentin and pregabalin, are used to treat a broad range of pain and mental health disorders. Gabapentin and pregabalin

are structural analogues of the neurotransmitter  $\gamma$ -aminobutyric acid, but these drugs bind to the  $\alpha_2$ - $\delta$  subunit of voltage-gated calcium channels. Gabapentin and pregabalin have exhibited efficacy for fibromyalgia<sup>151</sup> and several neuropathic pain conditions including postherpetic neuralgia, diabetic peripheral neuropathy, and neuropathic pain associated with spinal cord injury.<sup>150</sup> Although pregabalin has exhibited efficacy in the treatment of GAD,<sup>168</sup> the drug does not have Food and Drug Administration approval for this indication. Gabapentin may have mild anxiolytic effects, but numerous clinical trials have failed to exhibit clear efficacy for anxiety disorders.<sup>169</sup> In adults with fibromyalgia, pregabalin has been associated with reductions in posterior insular activity.<sup>170</sup>

**Serious Adverse Effects.** Serotonin syndrome is a medical emergency characterized by the clinical triad of autonomic and neuromuscular hyperactivity with associated delirium.<sup>171</sup> The syndrome is typically associated with selective serotonin reuptake inhibitors, but it has been reported with SNRIs and tramadol use.<sup>172</sup> Laboratory findings include metabolic acidosis and abnormalities consistent with rhabdomyolysis, renal failure, and coagulopathy. Although no single symptom or laboratory test is pathognomonic, a clinically oriented diagnostic algorithm has been developed with a sensitivity and specificity of 85% and 97%, respectively (Figure 4).<sup>171</sup>

Serotonin withdrawal syndrome, otherwise referred to as antidepressant discontinuation syndrome, is predominately characterized by sudden onset of dizziness, headache, nausea, fatigue, vomiting, ataxia, and paresthesias after abrupt discontinuation of antidepressant medications with serotonergic activity.<sup>173</sup> Proposed pathophysiological mechanisms include the rapid decline in serotonin availability, but alterations in noradrenergic and cholinergic activity could also be contributing factors. Symptoms may occur with use of SNRIs and TCAs. Regardless of the medication class, drugs with short half-lives are more likely to result in discontinuation symptoms.

The use of duloxetine, venlafaxine, and TCAs by children and adolescents, but not adults, has been associated with increased rates of suicidality and aggressive behavior.<sup>174</sup>



In adults, new treatment episodes of gabapentin, but not pregabalin, have been associated with increased rates of attempted suicide, completed suicide, and violent death.<sup>175</sup>

## CONCLUSION

Depression, anxiety, and SUDs are highly prevalent in chronic pain conditions frequently encountered in daily clinical practice. Consistent with the governing principles of the pain matrix, functional imaging studies suggest that shared neural mechanisms contribute to the bidirectional relationship between chronic pain and mental health disorders. Although self-report screening questionnaires can facilitate the identification of mental health problems, patients should be routinely questioned about the presence of suicidality and history of sexual violence. Behavioral interventions are associated with sustained improvements in a broad range of functional parameters, and use of analgesic medications with efficacy for both pain and mental health disorders

should be considered first-line agents in patients with chronic pain.

**Abbreviations and Acronyms:** ACC = anterior cingulate cortex; CBT = cognitive-behavioral therapy; GAD = generalized anxiety disorder; MPR = multidisciplinary pain rehabilitation; PD = personality disorder; PFC = prefrontal cortex; PTSD = posttraumatic stress disorder; SNRI = serotonin-norepinephrine reuptake inhibitor; TCA = tricyclic antidepressant

**Correspondence:** Address to W. Michael Hooten, MD, Division of Pain Medicine, Department of Anesthesiology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55902 (hooten.william@mayo.edu). Individual reprints of this article and a bound reprint of the entire Symposium on Pain Medicine will be available for purchase from our website [www.mayoclinicproceedings.org](http://www.mayoclinicproceedings.org).

**The Symposium on Pain Medicine will continue in an upcoming issue.**

## REFERENCES

- Henschke N, Kamper SJ, Maher CG. The epidemiology and economic consequences of pain. *Mayo Clin Proc.* 2015;90(1):139-147.
- Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication [published correction appears in *Arch Gen Psychiatry.* 2005;62(7):709. Merikangas, Kathleen R [added]]. *Arch Gen Psychiatry.* 2005;62(6):617-627.
- Steel Z, Marnane C, Iranpour C, et al. The global prevalence of common mental disorders: a systematic review and meta-analysis 1980-2013. *Int J Epidemiol.* 2014;43(2):476-493.
- Hooten WM, Cohen SP. Evaluation and treatment of low back pain: a clinically focused review for primary care specialists. *Mayo Clin Proc.* 2015;90(12):1699-1718.
- Melzack R. Phantom limbs and the concept of a neuromatrix. *Trends Neurosci.* 1990;13(3):88-92.
- Baliki MN, Apkarian AV. Nociception, pain, negative moods, and behavior selection. *Neuron.* 2015;87(3):474-491.
- Garcia-Larrea L, Peyron R. Pain matrices and neuropathic pain matrices: a review. *Pain.* 2013;154(suppl 1):S29-S43.
- Choi Y, Mayer TG, Williams MJ, Gatchel RJ. What is the best screening test for depression in chronic spinal pain patients? *Spine J.* 2014;14(7):1175-1182.
- Geisser ME, Roth RS, Robinson ME. Assessing depression among persons with chronic pain using the Center for Epidemiological Studies-Depression Scale and the Beck Depression Inventory: a comparative analysis. *Clin J Pain.* 1997;13(2):163-170.
- Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. *J Psychosom Res.* 2002;52(2):69-77.
- Julian LJ. Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A). *Arthritis Care Res (Hoboken).* 2011;63(suppl 11):S467-S472.
- Leyfer OT, Ruberg JL, Woodruff-Borden J. Examination of the utility of the Beck Anxiety Inventory and its factors as a screener for anxiety disorders. *J Anxiety Disord.* 2006;20(4):444-458.
- Kroenke K, Spitzer RL, Williams JB, Löwe B. The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. *Gen Hosp Psychiatry.* 2010;32(4):345-359.
- de Meneses-Gaya C, Zuairi AW, Loureiro SR, Crippa JA. Alcohol Use Disorders Identification Test (AUDIT): An updated systematic review of psychometric properties. *Psychol Neurosci.* 2009;2(1):83-97.
- Dhalla S, Kopec JA. The CAGE questionnaire for alcohol misuse: a review of reliability and validity studies. *Clin Invest Med.* 2007;30(1):33-41.
- Smith SM, Paillard F, McKeown A, et al. Instruments to identify prescription medication misuse, abuse, and related events in clinical trials: an ACTTION systematic review. *J Pain.* 2015;16(5):389-411.
- Aguglia A, Salvi V, Maina G, Rossetto I, Aguglia E. Fibromyalgia syndrome and depressive symptoms: comorbidity and clinical correlates. *J Affect Disord.* 2011;128(3):262-266.
- Häuser W, Jung E, Erbslöh-Möller B, et al. Validation of the Fibromyalgia Survey Questionnaire within a cross-sectional survey. *PLoS One.* 2012;7(5):e37504.
- Raphael KG, Janal MN, Nayak S, Schwartz JE, Gallagher RM. Psychiatric comorbidities in a community sample of women with fibromyalgia. *Pain.* 2006;124(1-2):117-125.
- Thieme K, Turk DC, Flor H. Comorbid depression and anxiety in fibromyalgia syndrome: relationship to somatic and psychosocial variables. *Psychosom Med.* 2004;66(6):837-844.
- Uguz F, Çiçek E, Salli A, et al. Axis I and Axis II psychiatric disorders in patients with fibromyalgia. *Gen Hosp Psychiatry.* 2010;32(1):105-107.
- Kudlow PA, Rosenblat JD, Weissman CR, et al. Prevalence of fibromyalgia and co-morbid bipolar disorder: a systematic review and meta-analysis. *J Affect Disord.* 2015;188:134-142.
- Arnold LM, Hudson JL, Keck PE, Auchenbach MB, Javaras KN, Hess EV. Comorbidity of fibromyalgia and psychiatric disorders. *J Clin Psychiatry.* 2006;67(8):1219-1225.
- Giannakopoulos NN, Keller L, Rammelsberg P, Kronmüller KT, Schmitter M. Anxiety and depression in patients with chronic temporomandibular pain and in controls. *J Dent.* 2010;38(5):369-376.
- Manfredini D, Borella L, Favero L, Ferronato G, Guardanardini L. Chronic pain severity and depression/somatization levels in TMD patients. *Int J Prosthodont.* 2010;23(6):529-534.
- Demyttenaere K, Bruffaerts R, Lee S, et al. Mental disorders among persons with chronic back or neck pain: results from the World Mental Health Surveys. *Pain.* 2007;129(3):332-342.
- Dersh J, Gatchel RJ, Mayer T, Polatin P, Temple OR. Prevalence of psychiatric disorders in patients with chronic disabling occupational spinal disorders. *Spine (Phila Pa 1976).* 2006;31(10):1156-1162.
- Reme SE, Tangen T, Moe T, Eriksen HR. Prevalence of psychiatric disorders in sick listed chronic low back pain patients. *Eur J Pain.* 2011;15(10):1075-1080.
- Von Korff M, Crane P, Lane M, et al. Chronic spinal pain and physical-mental comorbidity in the United States: results from the national comorbidity survey replication. *Pain.* 2005;113(3):331-339.
- Van Oudenhove L, Törnblom H, Störsrud S, Tack J, Simrén M. Depression and somatization are associated with increased postprandial symptoms in patients with irritable bowel syndrome. *Gastroenterology.* 2016;150(4):866-874.
- Balliet WE, Edwards-Hampton S, Borckardt JJ, et al. Depressive symptoms, pain, and quality of life among patients with nonalcohol-related chronic pancreatitis. *Pain Res Treat.* 2012;2012:978646.
- de Heer EW, Gerrits MM, Beekman AT, et al. The association of depression and anxiety with pain: a study from NESDA [published correction appears in *PLoS One.* 2014;9(12):e115077]. *PLoS One.* 2014;9(10):e106907.
- Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. *J Pain.* 2004;5(3):143-149.
- Berger A, Sadosky A, Dukes E, Edelsberg J, Oster G. Clinical characteristics and patterns of healthcare utilization in patients

- with painful neuropathic disorders in UK general practice: a retrospective cohort study. *BMC Neurol*. 2012;12:8.
35. Gore M, Dukes E, Rowbotham DJ, Tai KS, Leslie D. Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings. *Eur J Pain*. 2007;11(6):652-664.
  36. Yawn BP, Wollan PC, Weingarten TN, Watson JC, Hooten WM, Melton LJ III. The prevalence of neuropathic pain: clinical evaluation compared with screening tools in a community population [published correction appears in *Pain Med*. 2011;12(8):1294]. *Pain Med*. 2009;10(3):586-593.
  37. McWilliams LA, Cox BJ, Enns MW. Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample. *Pain*. 2003;106(1-2):127-133.
  38. McWilliams LA, Goodwin RD, Cox BJ. Depression and anxiety associated with three pain conditions: results from a nationally representative sample. *Pain*. 2004;111(1-2):77-83.
  39. Oedegaard KJ, Neckelmann D, Mykletun A, et al. Migraine with and without aura: association with depression and anxiety disorder in a population-based study: the HUNT Study. *Cephalalgia*. 2006;26(1):1-6.
  40. Saunders K, Merikangas K, Low NC, Von Korff M, Kessler RC. Impact of comorbidity on headache-related disability. *Neurology*. 2008;70(7):538-547.
  41. Zwart JA, Dyb G, Hagen K, et al. Depression and anxiety disorders associated with headache frequency: the Nord-Trøndelag Health Study. *Eur J Neurol*. 2003;10(2):147-152.
  42. Clemens JQ, Brown SO, Calhoun EA. Mental health diagnoses in patients with interstitial cystitis/painful bladder syndrome and chronic prostatitis/chronic pelvic pain syndrome: a case/control study. *J Urol*. 2008;180(4):1378-1382.
  43. Masheb RM, Wang E, Lozano C, Kerns RD. Prevalence and correlates of depression in treatment-seeking women with vulvodynia. *J Obstet Gynaecol*. 2005;25(8):786-791.
  44. Nickel JC, Tripp DA; International Interstitial Cystitis Study Group. Clinical and psychological parameters associated with pain pattern phenotypes in women with interstitial cystitis/bladder pain syndrome. *J Urol*. 2015;193(1):138-144.
  45. Riegel B, Bruenahl CA, Ahayi S, Bingel U, Fisch M, Löwe B. Assessing psychological factors, social aspects and psychiatric co-morbidity associated with Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) in men—a systematic review. *J Psychosom Res*. 2014;77(5):333-350.
  46. Samplaski MK, Li J, Shoskes DA. Clustering of UPOINT domains and subdomains in men with chronic prostatitis/chronic pelvic pain syndrome and contribution to symptom severity. *J Urol*. 2012;188(5):1788-1793.
  47. Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. *Rheumatology (Oxford)*. 2013;52(12):2136-2148.
  48. Murphy LB, Sacks JJ, Brady TJ, Hootman JM, Chapman DP. Anxiety and depression among US adults with arthritis: prevalence and correlates. *Arthritis Care Res (Hoboken)*. 2012;64(7):968-976.
  49. Stang PE, Brandenburg NA, Lane MC, Merikangas KR, Von Korff MR, Kessler RC. Mental and physical comorbid conditions and days in role among persons with arthritis. *Psychosom Med*. 2006;68(1):152-158.
  50. Burnis JL, Cyders MA, de Leeuw R, Smith GT, Carlson CR. Posttraumatic stress disorder symptoms and chronic orofacial pain: an empirical examination of the mutual maintenance model. *J Orofac Pain*. 2009;23(3):243-252.
  51. De Leeuw R, Bertoli E, Schmidt JE, Carlson CR. Prevalence of post-traumatic stress disorder symptoms in orofacial pain patients. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2005;99(5):558-568.
  52. Monteiro DR, Zuim PR, Pesqueira AA, Ribeiro Pdo P, Garcia AR. Relationship between anxiety and chronic orofacial pain of temporomandibular disorder in a group of university students. *J Prosthodont Res*. 2011;55(3):154-158.
  53. Lamvu G, Nguyen RH, Burrows LJ, et al. The evidence-based Vulvodynia Assessment Project: a national registry for the study of vulvodynia. *J Reprod Med*. 2015;60(5-6):223-235.
  54. Alonso-Morán E, Orueta JF, Fraile Esteban JI, et al. The prevalence of diabetes-related complications and multimorbidity in the population with type 2 diabetes mellitus in the Basque Country. *BMC Public Health*. 2014;14:1059.
  55. Demjanovic Dobrota V, Hrabac P, Skegrod D, et al. The impact of neuropathic pain and other comorbidities on the quality of life in patients with diabetes. *Health Qual Life Outcomes*. 2014;12:171.
  56. Zhao Y, Liu J, Zhao Y, Thethi T, Fonseca V, Shi L. Predictors of duloxetine versus other treatments among veterans with diabetic peripheral neuropathic pain: a retrospective study. *Pain Pract*. 2012;12(5):366-373.
  57. Ciaramella A, Poli P. Chronic low back pain: perception and coping with pain in the presence of psychiatric comorbidity. *J Nerv Ment Dis*. 2015;203(8):632-640.
  58. Janssens KA, Zijlema WL, Joustra ML, Rosmalen JG. Mood and anxiety disorders in chronic fatigue syndrome, fibromyalgia, and irritable bowel syndrome: results from the LifeLines Cohort Study. *Psychosom Med*. 2015;77(4):449-457.
  59. Carroll LJ, Cassidy JD, Côté P. Factors associated with the onset of an episode of depressive symptoms in the general population. *J Clin Epidemiol*. 2003;56(7):651-658.
  60. Carroll LJ, Cassidy JD, Côté P. Depression as a risk factor for onset of an episode of troublesome neck and low back pain. *Pain*. 2004;107(1-2):134-139.
  61. Currie SR, Wang J. Chronic back pain and major depression in the general Canadian population. *Pain*. 2004;107(1-2):54-60.
  62. Currie SR, Wang J. More data on major depression as an antecedent risk factor for first onset of chronic back pain. *Psychol Med*. 2005;35(9):1275-1282.
  63. Baliki MN, Chialvo DR, Geha PY, et al. Chronic pain and the emotional brain: specific brain activity associated with spontaneous fluctuations of intensity of chronic back pain. *J Neurosci*. 2006;26(47):12165-12173.
  64. Berman SM, Naliboff BD, Suyenobu B, et al. Reduced brainstem inhibition during anticipated pelvic visceral pain correlates with enhanced brain response to the visceral stimulus in women with irritable bowel syndrome. *J Neurosci*. 2008;28(2):349-359.
  65. Jensen KB, Kosek E, Petzke F, et al. Evidence of dysfunctional pain inhibition in fibromyalgia reflected in rACC during provoked pain. *Pain*. 2009;144(1-2):95-100.
  66. Hashmi JA, Baliki MN, Huang L, et al. Shape shifting pain: chronicification of back pain shifts brain representation from nociceptive to emotional circuits. *Brain*. 2013;136(pt 9):2751-2768.
  67. Diener C, Kuehner C, Brusniak W, Uhl B, Wessa M, Flor H. A meta-analysis of neurofunctional imaging studies of emotion and cognition in major depression. *Neuroimage*. 2012;61(3):677-685.
  68. Mutschler I, Ball T, Wankerl J, Strigo IA. Pain and emotion in the insular cortex: evidence for functional reorganization in major depression. *Neurosci Lett*. 2012;520(2):204-209.
  69. Bruffaerts R, Demyttenaere K, Kessler RC, et al. The associations between preexisting mental disorders and subsequent onset of chronic headaches: a worldwide epidemiologic perspective. *J Pain*. 2015;16(1):42-52.
  70. Hsieh JC, Hannerz J, Ingvar M. Right-lateralised central processing for pain of nitroglycerin-induced cluster headache. *Pain*. 1996;67(1):59-68.
  71. Davidson RJ, Abercrombie H, Nitschke JB, Putnam K. Regional brain function, emotion and disorders of emotion. *Curr Opin Neurobiol*. 1999;9(2):228-234.

72. Rosen SD, Paulesu E, Frith CD, et al. Central nervous pathways mediating angina pectoris. *Lancet*. 1994;344(8916):147-150.
73. Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. *N Engl J Med*. 2016;374(2):154-163.
74. Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. *N Engl J Med*. 2015;372(3):241-248.
75. Martell BA, O'Connor PG, Kerns RD, et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. *Ann Intern Med*. 2007;146(2):116-127.
76. Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. *Pain*. 2015;156(4):569-576.
77. Boscarino JA, Hoffman SN, Han JJ. Opioid-use disorder among patients on long-term opioid therapy: impact of final DSM-5 diagnostic criteria on prevalence and correlates. *Subst Abuse Rehabil*. 2015;6:83-91.
78. Boscarino JA, Rukstalis M, Hoffman SN, et al. Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. *Addiction*. 2010;105(10):1776-1782.
79. Boscarino JA, Rukstalis MR, Hoffman SN, et al. Prevalence of prescription opioid-use disorder among chronic pain patients: comparison of the DSM-5 vs. DSM-4 diagnostic criteria. *J Addict Dis*. 2011;30(3):185-194.
80. Reisfield GM, Wasan AD, Jamison RN. The prevalence and significance of cannabis use in patients prescribed chronic opioid therapy: a review of the extant literature. *Pain Med*. 2009;10(8):1434-1441.
81. Alford DP, German JS, Samet JH, Cheng DM, Lloyd-Travaglini CA, Saitz R. Primary care patients with drug use report chronic pain and self-medicate with alcohol and other drugs. *J Gen Intern Med*. 2016;31(5):486-491.
82. Jamison RN, Kauffman J, Katz NP. Characteristics of methadone maintenance patients with chronic pain. *J Pain Symptom Manage*. 2000;19(1):53-62.
83. Rosenblum A, Joseph H, Fong C, Kipnis S, Cleland C, Portenoy RK. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. *JAMA*. 2003;289(18):2370-2378.
84. Tegethoff M, Belardi A, Stalujanis E, Meinschmidt G. Comorbidity of mental disorders and chronic pain: chronology of onset in adolescents of a national representative cohort. *J Pain*. 2015;16(10):1054-1064.
85. Scott KM, Lim C, Al-Hamzawi A, et al. Association of mental disorders with subsequent chronic physical conditions: World Mental Health surveys from 17 countries. *JAMA Psychiatry*. 2016;73(2):150-158.
86. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. *Am J Psychiatry*. 2005;162(8):1403-1413.
87. Morales M, Pickel VM. Insights to drug addiction derived from ultrastructural views of the mesocorticolimbic system. *Ann NY Acad Sci*. 2012;1248:71-88.
88. Apkarian AV, Neugebauer V, Koob G, et al. Neural mechanisms of pain and alcohol dependence. *Pharmacol Biochem Behav*. 2013;112:34-41.
89. Egli M, Koob GF, Edwards S. Alcohol dependence as a chronic pain disorder. *Neurosci Biobehav Rev*. 2012;36(10):2179-2192.
90. Joseph EK, Reichling DB, Levine JD. Shared mechanisms for opioid tolerance and a transition to chronic pain. *J Neurosci*. 2010;30(13):4660-4666.
91. Centers for Disease Control and Prevention, National Center for Injury and Prevention and Control. Web-based Injury Statistics Query and Reporting System (WISQARS). [http://www.cdc.gov/injury/wisqars/pdf/leading\\_causes\\_of\\_death\\_by\\_age\\_group\\_2013-a.pdf](http://www.cdc.gov/injury/wisqars/pdf/leading_causes_of_death_by_age_group_2013-a.pdf). Accessed June 1, 2016.
92. Hassett AL, Aquino JK, Ilgen MA. The risk of suicide mortality in chronic pain patients. *Curr Pain Headache Rep*. 2014;18(8):436.
93. Ilgen MA, Zivin K, Austin KL, et al. Severe pain predicts greater likelihood of subsequent suicide. *Suicide Life Threat Behav*. 2010;40(6):597-608.
94. Cheatle MD, Wasser T, Foster C, Olugbodi A, Bryan J. Prevalence of suicidal ideation in patients with chronic non-cancer pain referred to a behaviorally based pain program. *Pain Physician*. 2014;17(3):E359-E367.
95. Calandre EP, Navajas-Rojas MA, Ballesteros J, Garcia-Carrillo J, Garcia-Leiva JM, Rico-Villademoros F. Suicidal ideation in patients with fibromyalgia: a cross-sectional study. *Pain Pract*. 2015;15(2):168-174.
96. Triñanes Y, González-Villar A, Gómez-Perretta C, Carrillo-de-la-Peña MT. Suicidality in chronic pain: predictors of suicidal ideation in fibromyalgia. *Pain Pract*. 2015;15(4):323-332.
97. Calati R, Laglaoui Bakhiyi C, Artero S, Ilgen M, Courtet P. The impact of physical pain on suicidal thoughts and behaviors: meta-analyses. *J Psychiatr Res*. 2015;71:16-32.
98. Breiding MJ, Smith SG, Basile KC, Walters ML, Chen J, Merrick MT. Prevalence and characteristics of sexual violence, stalking, and intimate partner violence victimization—national intimate partner and sexual violence survey, United States, 2011. *MMWR Surveill Summ*. 2014;63(8):1-18.
99. Afari N, Ahumada SM, Wright LJ, et al. Psychological trauma and functional somatic syndromes: a systematic review and meta-analysis. *Psychosom Med*. 2014;76(1):2-11.
100. Paras ML, Murad MH, Chen LP, et al. Sexual abuse and lifetime diagnosis of somatic disorders: a systematic review and meta-analysis. *JAMA*. 2009;302(5):550-561.
101. Ehler U. Enduring psychobiological effects of childhood adversity. *Psychoneuroendocrinology*. 2013;38(9):1850-1857.
102. Spiegel DR, Shaikat AM, McCroskey AL, et al. Conceptualizing a subtype of patients with chronic pain: the necessity of obtaining a history of sexual abuse. *Int J Psychiatry Med*. 2016;51(1):84-103.
103. Evers AW, Kraaijmaat FW, van Riel PL, Bijlsma JW. Cognitive, behavioral and physiological reactivity to pain as a predictor of long-term pain in rheumatoid arthritis patients. *Pain*. 2001;93(2):139-146.
104. Cvijetic S, Bobic J, Grazio S, Uremovic M, Nemcic T, Krapac L. Quality of life, personality and use of pain medication in patients with chronic back pain. *Appl Res Qual Life*. 2014;9(2):401-411.
105. Ramírez-Maestre C, López Martínez AE, Zarazaga RE. Personality characteristics as differential variables of the pain experience. *J Behav Med*. 2004;27(2):147-165.
106. Harkins SW, Price DD, Braith J. Effects of extraversion and neuroticism on experimental pain, clinical pain, and illness behavior. *Pain*. 1989;36(2):209-218.
107. Kadimpati S, Zale EL, Hooten WM, Ditre JW, Warner DO. Correction: associations between neuroticism and depression in relation to catastrophizing and pain-related anxiety in chronic pain patients. *PLoS One*. 2015;10(6):e0129871.
108. Tyrer P, Reed GM, Crawford MJ. Classification, assessment, prevalence, and effect of personality disorder. *Lancet*. 2015;385(9969):717-726.
109. Weisberg JN. Personality and personality disorders in chronic pain. *Curr Rev Pain*. 2000;4(1):60-70.
110. Dixon-Gordon KL, Turner BJ, Chapman AL. Psychotherapy for personality disorders. *Int Rev Psychiatry*. 2011;23(3):282-302.
111. Agaku IT, King BA, Dube SR. Centers for Disease Control and Prevention (CDC). Current cigarette smoking among adults—United States, 2005-2012. *MMWR Morb Mortal Wkly Rep*. 2014;63(2):29-34.

112. Orhurhu VJ, Pittelkow TP, Hooten WM. Prevalence of smoking in adults with chronic pain. *Tob Induc Dis*. 2015; 13(1):17.
113. Centers for Disease Control and Prevention (CDC). Vital signs: current cigarette smoking among adults aged  $\geq 18$  years—United States, 2005-2010. *MMWR Morb Mortal Wkly Rep*. 2011;60(35):1207-1212.
114. Hooten WM, Shi Y, Gazelka HM, Warner DO. The effects of depression and smoking on pain severity and opioid use in patients with chronic pain. *Pain*. 2011;152(1):223-229.
115. Hooten WM, Townsend CO, Bruce BK, et al. Effects of smoking status on immediate treatment outcomes of multidisciplinary pain rehabilitation. *Pain Med*. 2009;10(2):347-355.
116. Hooten WM, Townsend CO, Bruce BK, Shi Y, Warner DO. Sex differences in characteristics of smokers with chronic pain undergoing multidisciplinary pain rehabilitation. *Pain Med*. 2009;10(8):1416-1425.
117. Hooten WM, Townsend CO, Bruce BK, Warner DO. The effects of smoking status on opioid tapering among patients with chronic pain. *Anesth Analg*. 2009;108(1):308-315.
118. Kishioka S, Kiguchi N, Kobayashi Y, Saika F. Nicotine effects and the endogenous opioid system. *J Pharmacol Sci*. 2014; 125(2):117-124.
119. Hooten WM, Vickers KS, Shi Y, et al. Smoking cessation and chronic pain: patient and pain medicine physician attitudes. *Pain Pract*. 2011;11(6):552-563.
120. Hooten WM, Townsend CO, Hays JT, et al. A cognitive behavioral smoking abstinence intervention for adults with chronic pain: a randomized controlled pilot trial. *Addict Behav*. 2014;39(3):593-599.
121. Vlaeyen JW, Linton SJ. Fear-avoidance and its consequences in chronic musculoskeletal pain: a state of the art. *Pain*. 2000; 85(3):317-332.
122. Linton SJ, Shaw WS. Impact of psychological factors in the experience of pain. *Phys Ther*. 2011;91(5):700-711.
123. Lloyd DM, Helbig T, Findlay G, Roberts N, Nummikko T. Brain areas involved in anticipation of clinically-relevant pain in low back pain populations with high levels of pain behaviour. *J Pain*. 2016;17(5):577-587.
124. Otis JD, Pincus DB, Murawski ME. Cognitive behavioral therapy in pain management. In: Ebert MH, Kerns RD, eds. *Behavioral and Psychopharmacologic Pain Management*. Cambridge, UK: Cambridge University Press; 2011:184-200.
125. Pence LE, Thorn BE, Davis AM. Cognitive coping strategies in pain management. In: Ebert MH, Kerns RD, eds. *Behavioral and Psychopharmacologic Pain Management*. Cambridge, UK: Cambridge University Press; 2011:214-235.
126. Bernardy K, Füber N, Köllner V, Häuser W. Efficacy of cognitive-behavioral therapies in fibromyalgia syndrome—a systematic review and metaanalysis of randomized controlled trials. *J Rheumatol*. 2010;37(10):1991-2005.
127. Butler AC, Chapman JE, Foman EM, Beck AT. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. *Clin Psychol Rev*. 2006;26(1):17-31.
128. Richmond H, Hall AM, Copey B, et al. The effectiveness of cognitive behavioural treatment for non-specific low back pain: a systematic review and meta-analysis. *PLoS One*. 2015; 10(8):e0134192.
129. Jensen KB, Kosek E, Wicksell R, et al. Cognitive behavioral therapy increases pain-evoked activation of the prefrontal cortex in patients with fibromyalgia [published correction appears in *Pain*. 2012;153(9):1982]. *Pain*. 2012;153(7): 1495-1503.
130. Hayes SC, Levin ME, Plumb-Villardaga J, Villatte JL, Pistorello J. Acceptance and commitment therapy and contextual behavioral science: examining the progress of a distinctive model of behavioral and cognitive therapy. *Behav Ther*. 2013;44(2): 180-198.
131. Veehof MM, Oskam MJ, Schreurs KM, Bohlmeijer ET. Acceptance-based interventions for the treatment of chronic pain: a systematic review and meta-analysis. *Pain*. 2011;152(3): 533-542.
132. Veehof MM, Trompetter HR, Bohlmeijer ET, Schreurs KM. Acceptance- and mindfulness-based interventions for the treatment of chronic pain: a meta-analytic review. *Cogn Behav Ther*. 2016;45(1):5-31.
133. Goyal M, Singh S, Sibinga EM, et al. Meditation programs for psychological stress and well-being: a systematic review and meta-analysis. *JAMA Intern Med*. 2014;174(3):357-368.
134. Bawa FL, Mercer SW, Atherton RJ, et al. Does mindfulness improve outcomes in patients with chronic pain? Systematic review and meta-analysis. *Br J Gen Pract*. 2015;65(635): e387-e400.
135. Tang YY, Hölzel BK, Posner MI. The neuroscience of mindfulness meditation. *Nat Rev Neurosci*. 2015;16(4):213-225.
136. Townsend CO, Bruce BK, Hooten WM, Rome JD. The role of mental health professionals in multidisciplinary pain rehabilitation programs. *J Clin Psychol*. 2006;62(11):1433-1443.
137. Bema C, Kulich RJ, Rathmell JP. Tapering long-term opioid therapy in chronic noncancer pain: evidence and recommendations for everyday practice. *Mayo Clin Proc*. 2015;90(6): 828-842.
138. Kamper SJ, Apeldoorn AT, Chiarotto A, et al. Multidisciplinary biopsychosocial rehabilitation for chronic low back pain: Cochrane systematic review and meta-analysis. *BMJ*. 2015; 350:h444.
139. Sletten CD, Kurklsinsky S, Chinburapa V, Ghazi S. Economic analysis of a comprehensive pain rehabilitation program: a collaboration between Florida Blue and Mayo Clinic Florida. *Pain Med*. 2015;16(5):898-904.
140. Hooten WM, Qu W, Townsend CO, Judd JW. Effects of strength vs aerobic exercise on pain severity in adults with fibromyalgia: a randomized equivalence trial. *Pain*. 2012;153(4): 915-923.
141. Hooten WM, Rosenberg CJ, Eldrige JS, Qu W. Knee extensor strength is associated with pressure pain thresholds in adults with fibromyalgia. *PLoS One*. 2013;8(4):e59930.
142. Hooten WM, Smith JM, Eldrige JS, Olsen DA, Mauck WVD, Moeschler SM. Pain severity is associated with muscle strength and peak oxygen uptake in adults with fibromyalgia. *J Pain Res*. 2014;7:237-242.
143. Cunningham JL, Rome JD, Kerkvliet JL, Townsend CO. Reduction in medication costs for patients with chronic nonmalignant pain completing a pain rehabilitation program: a prospective analysis of admission, discharge, and 6-month follow-up medication costs. *Pain Med*. 2009;10(5):787-796.
144. Hooten WM. Commentary: the paradox of analgesic medication elimination. *Pain Med*. 2009;10(5):797-798.
145. Crisostomo RA, Schmidt JE, Hooten WM, Kerkvliet JL, Townsend CO, Bruce BK. Withdrawal of analgesic medication for chronic low-back pain patients: improvement in outcomes of multidisciplinary rehabilitation regardless of surgical history. *Am J Phys Med Rehabil*. 2008;87(7):527-536.
146. Hooten WM, Townsend CO, Sletten CD, Bruce BK, Rome JD. Treatment outcomes after multidisciplinary pain rehabilitation with analgesic medication withdrawal for patients with fibromyalgia. *Pain Med*. 2007;8(1):8-16.
147. Townsend CO, Kerkvliet JL, Bruce BK, et al. A longitudinal study of the efficacy of a comprehensive pain rehabilitation program with opioid withdrawal: comparison of treatment outcomes based on opioid use status at admission. *Pain*. 2008;140(1):177-189.
148. Hochberg MC, Wohlreich M, Gaynor P, Hanna S, Risser R. Clinically relevant outcomes based on analysis of pooled data from 2 trials of duloxetine in patients with knee osteoarthritis. *J Rheumatol*. 2012;39(2):352-358.
149. Häuser W, Petzke F, Üçeyler N, Sommer C. Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. *Rheumatology (Oxford)*. 2011;50(3):532-543.

150. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. *Lancet Neurol*. 2015;14(2):162-173.
151. Häuser W, Bernardy K, Uçeyler N, Sommer C. Treatment of fibromyalgia syndrome with gabapentin and pregabalin—a meta-analysis of randomized controlled trials. *Pain*. 2009;145(1-2):69-81.
152. Marangell LB, Clauw DJ, Choy E, et al. Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: secondary analyses of four pooled randomized controlled trials of duloxetine. *Pain*. 2011;152(1):31-37.
153. Häuser W, Bernardy K, Uçeyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. *JAMA*. 2009;301(2):198-209.
154. Wang ZY, Shi SY, Li SJ, et al. Efficacy and safety of duloxetine on osteoarthritis knee pain: a meta-analysis of randomized controlled trials. *Pain Med*. 2015;16(7):1373-1385.
155. Bradley AJ, Lenox-Smith AJ. Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials. *J Psychopharmacol*. 2013;27(8):740-758.
156. Dell'Osso B, Buoli M, Baldwin DS, Altamura AC. Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy. *Hum Psychopharmacol*. 2010;25(1):17-29.
157. Fishbain DA, Cole B, Lewis JE, Gao J. Does pain interfere with antidepressant depression treatment response and remission in patients with depression and pain? An evidence-based structured review. *Pain Med*. 2014;15(9):1522-1539.
158. Kroenke K, Bair MJ, Damush TM, et al. Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial. *JAMA*. 2009;301(20):2099-2110.
159. López-Solà M, Pujol J, Hernández-Ribas R, et al. Effects of duloxetine treatment on brain response to painful stimulation in major depressive disorder. *Neuropsychopharmacology*. 2010;35(11):2305-2317.
160. Mainguy Y. Functional magnetic resonance imagery (fMRI) in fibromyalgia and the response to milnacipran. *Hum Psychopharmacol*. 2009;24(suppl 1):S19-S23.
161. Dick IE, Brochu RM, Purohit Y, Kaczorowski GJ, Martin WJ, Priest BT. Sodium channel blockade may contribute to the analgesic efficacy of antidepressants. *J Pain*. 2007;8(4):315-324.
162. Li YF, Zhang YZ, Liu YQ, et al. Inhibition of *N*-methyl-D-aspartate receptor function appears to be one of the common actions for antidepressants. *J Psychopharmacol*. 2006;20(5):629-635.
163. Benbouzid M, Gavériaux-Ruff C, Yalcin I, et al. Delta-opioid receptors are critical for tricyclic antidepressant treatment of neuropathic allodynia. *Biol Psychiatry*. 2008;63(6):633-636.
164. Tata LJ, West J, Smith C, et al. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. *Heart*. 2005;91(4):465-471.
165. Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. *Clin Pharmacol Ther*. 2004;75(3):234-241.
166. Staiger TO, Gaster B, Sullivan MD, Deyo RA. Systematic review of antidepressants in the treatment of chronic low back pain. *Spine (Phila Pa 1976)*. 2003;28(22):2540-2545.
167. Morgan V, Pickens D, Gautam S, Kessler R, Mertz H. Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. *Gut*. 2005;54(5):601-607.
168. Perna G, Alciati A, Riva A, Micieli W, Caldirola D. Long-term pharmacological treatments of anxiety disorders: an updated systematic review. *Curr Psychiatry Rep*. 2016;18(3):23.
169. Berlin RK, Butler PM, Perloff MD. Gabapentin therapy in psychiatric disorders: a systematic review. *Prim Care Companion CNS Disord*. 2015;17(5).
170. Harris RE, Napadow V, Huggins JP, et al. Pregabalin rectifies aberrant brain chemistry, connectivity, and functional response in chronic pain patients. *Anesthesiology*. 2013;119(6):1453-1464.
171. Boyer EW, Shannon M. The serotonin syndrome [published corrections appear in *N Engl J Med*. 2007;356(23):2437 and *N Engl J Med*. 2009;361(17):1714]. *N Engl J Med*. 2005;352(11):1112-1120.
172. Gillman PK. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. *Biol Psychiatry*. 2006;59(11):1046-1051.
173. Black K, Shea C, Dursun S, Kutcher S. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. *J Psychiatry Neurosci*. 2000;25(3):255-261.
174. Sharma T, Guskis LS, Freund N, Göttsche PC. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. *BMJ*. 2016;352:i65.
175. Patomo E, Bohn RL, Wahl PM, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death [published correction appears in *JAMA*. 2010;303(22):2252. Dosage error in article text]. *JAMA*. 2010;303(14):1401-1409.